Company Statements

Indivior Attends the Office of National Drug Control Policy’s 2024 Opioid Overdose Reversal Medication (OORM) Manufacturers Meeting on June 4, 2024


At Indivior, we commend the Office of National Drug Control Policy’s (ONDCP) leadership and collaboration, including convening the 2024 Opioid Overdose Reversal Medication (OORM) Manufacturers Meeting. The devastating impact of opioid overdose cannot be overstated, and it requires a collective effort from all stakeholders to combat this crisis effectively. As a leading pharmaceutical company working to change patients’ lives by pioneering life-transforming treatment for substance abuse and overdose, we are committed to collaborating with stakeholders at all levels to ensure that there is nationwide access to all life-saving medications, including all FDA-approved overdose reversal agents. 

Indivior’s philanthropic program, Indivior CARES, works through collaborations with like-minded non-profit organizations across the U.S. to help stem the tragic loss of life from overdose and encourage open dialogue to reduce stigma associated with addiction and co-occurring mental health diseases. Through Indivior CARES, we provide resources and increase access to evidence-based treatment options for patients while cultivating a better understanding of addiction. 

As we continue to navigate the complexities of the opioid epidemic, Indivior remains resolute in our mission. We extend our gratitude to the ONDCP for convening today’s vital meeting and reaffirm our commitment to collaborative efforts aimed at ending the opioid crisis.